$0.52
+3.36%Sep 14, 2026, 11:00 UTC
Pasithea Therapeutics announced it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference in Vienna, Austria, on November 12-14, 2026.
Source:Jun 2, 2026, 11:02 UTC
The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.
Source: